The Life Sciences team advised Vibrant Therapeutics (“Vibrant”) on raising $61 million in new financing. The financing includes new investors Pfizer Ventures and Apricot Capital with participation from Bayland Capital, HSG, Northern Light Venture Capital, and First Principle Venture Limited. This brings Vibrant’s total capital raised to $100 million. Proceeds from the financing will be used to advance Vibrant’s robust pipeline, as well as further develop its proprietary next-generation drug design platform and expand the company’s team to support continued growth and global development activities.
Vibrant Therapeutics is a clinical-stage biotechnology company developing intelligent, logic-gated therapeutics designed to selectively activate in the desired disease microenvironment. Leveraging an integrated computational and experimental (“dry-wet”) R&D platform, the company is advancing a pipeline of innovative first-in-class/best-in-class programs, including masked T-cell engagers for solid tumors, and exploring broader applications of its technology across additional modalities and therapeutic areas. Founded by Larry Wang, Ph.D., co-founder of GenScript, Vibrant is led by a team of seasoned biotech executives formerly of Schering-Plough, Merck, and GenScript. Vibrant is headquartered in Guangzhou, China and Cambridge, Massachusetts.
The Goodwin deal team was led by Wenseng “Wendy” Pan and consisted of Kevin Guan and Yichen Xu.
For more information on the deal, please read the press release.